Your Health, We Care
Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations. Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for Sunitinib when it is co-administered with strong CYP3A4 inhibitors.
Co-administration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations. Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for Sunitinib when it must be co-administered with CYP3A4 inducers.
Sunitinib is associated with QTc interval prolongation. Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval.
from FDA，2021.08
